New UTI Pill Utebzi (Tebipenem): Dosing, Side Effects & How to Save

Utebzi (tebipenem pivoxil) is a 300-mg tablet taken as two tablets every six hours for 7–10 days to cure complicated urinary tract infections, including kidney infections, caused by resistant Enterobacterales. In a pivotal Phase 3 study it achieved a 93 percent clinical cure rate-matching IV ertapenem-without an infusion or hospital stay. Adults who have limited or no oral treatment options qualify, and most can cut out-of-pocket costs by up to 82 percent using an Rx.com discount card.

• The FDA approved Utebzi on June 17 2026 as the first oral carbapenem for complicated UTIs. (fda.gov)
• The recommended dose is 600 mg orally every 6 hours (four doses daily) for 7–10 days. (accessdata.fda.gov)
• Phase 3 ADAPT-PO showed 93.1 percent clinical cure with tebipenem versus 93.6 percent with IV ertapenem. (nejm.org)
• Common side-effects include diarrhea, headache and nausea, each in ≥1 percent of patients. (accessdata.fda.gov)
• Average inpatient IV carbapenem care costs ≈ $3,764 per day, so switching to Utebzi can save $10,000 + per admission. (pmc.ncbi.nlm.nih.gov)
• GoodRx users save an average 82 percent on retail drug prices-bring a free Rx.com coupon to the pharmacy. (investors.goodrx.com)

What Utebzi Is and Why It Matters

Utebzi is the first FDA-approved oral pro-drug of the carbapenem antibiotic tebipenem. Carbapenems were previously IV-only, so patients with extended-spectrum β-lactamase (ESBL) or fluoroquinolone-resistant E. coli often needed hospitalization for drugs like ertapenem or meropenem. Utebzi closes that gap by delivering comparable plasma levels in a swallowable tablet.

Definition (60 words): Tebipenem pivoxil is an orally bioavailable carbapenem that, once absorbed, is hydrolyzed to active tebipenem to inhibit bacterial cell-wall synthesis in gram-negative uropathogens, including ESBL-positive Enterobacterales. Approved in June 2026, Utebzi is indicated for adult complicated urinary tract infections (cUTI) and pyelonephritis when few or no oral options remain. (fda.gov)

For a refresher on symptoms and prevention of UTIs, see our UTI guide.

Who Qualifies for Utebzi

The label restricts Utebzi to adults with limited or no alternative oral agents. That generally means:

• Confirmed or strongly suspected ESBL-producing E. coli, K. pneumoniae or E. cloacae
• Fluoroquinolone or trimethoprim-sulfamethoxazole resistance
• Intolerance or allergy to first-line oral drugs like amoxicillin or trimethoprim-sulfamethoxazole
• eGFR ≥ 15 mL/min (dose-adjust if < 60 mL/min)
• No history of primary carnitine deficiency

Clinicians should document culture results to satisfy insurers that prior oral options have failed-critical for prior authorization approval.

How Tebipenem Fights Resistant Bugs

Tebipenem binds penicillin-binding proteins (PBPs) 2 and 3, blocking the final transpeptidation step of cell-wall synthesis. In vitro studies show minimum inhibitory concentrations (MIC₉₀) of ≤ 0.06 µg/mL for ESBL-positive E. coli isolates-well below achievable serum levels of 8 µg/mL after a 600 mg dose. (pmc.ncbi.nlm.nih.gov)

Broad spectrum without pseudomonal activity: Utebzi covers most urinary Enterobacterales but lacks reliable activity against Pseudomonas or Acinetobacter, so IV options remain necessary for those pathogens.

Exact Dosing & Renal Adjustments

The standard adult dose is 600 mg (two 300 mg tablets) every 6 hours for 7–10 days. Utebzi can be taken with or without food and does not require a loading dose.

Miss a dose? Take it as soon as possible unless it is almost time for the next dose-then skip. Never double up.

Side-Effects and Safety Signals

In trials, Utebzi’s safety profile mirrored IV carbapenems. The most common events (≥ 1 percent) were diarrhea (8 percent), headache (4 percent), and nausea (3 percent). Seizures occurred in < 0.1 percent. (accessdata.fda.gov)

Watch for carnitine loss: Because the pro-drug contains pivalate, treatment beyond 10 days can trigger carnitine depletion-hence the strict duration limit in the label.

Resistance & Stewardship Concerns

Overuse risks eroding this “last-line” option. Laboratory surveillance from 2018-2020 found tebipenem MIC₅₀/MIC₉₀ of 0.03/0.06 µg/mL against ESBL producers, but carbapenemase-positive isolates were uniformly resistant. (pmc.ncbi.nlm.nih.gov)

To slow resistance, infectious disease guidelines recommend reserving Utebzi for ESBL infections after oral β-lactams and fluoroquinolones fail, similar to IV carbapenem stewardship rules.

Cost: Utebzi vs IV Therapy & How to Save

No wholesale acquisition cost (WAC) has been publicly posted as of July 2026, but launch-year oral antibiotic analogs (e.g., omadacycline) debuted at about $2,500–$3,000 per 7-day course. In contrast, IV ertapenem entails drug plus inpatient room, PICC and nursing costs that average $3,764 per hospital day. A 5-day stay can exceed $18,000. (pmc.ncbi.nlm.nih.gov)

*Drug cost estimates from published WAC or GoodRx retail averages; facility cost from average U.S. inpatient day.

How to pay less:

• Rx.com coupon: Print or text yourself a free card from Rx.com; GoodRx data show users save 82 percent on average. (investors.goodrx.com)
• Prior authorization tips: Attach culture and susceptibility, note “no effective oral alternatives,” and reference FDA indication 1.1 in the label.
• Medicare Part D: Request tier exception citing hospital cost-avoidance.
• Manufacturer assistance: GSK’s launch voucher (up to two fills at $0) is expected Q4 2026-ask the pharmacy to enroll you.

Need a standard UTI option? First-line agents like doxycycline or amoxicillin remain inexpensive and may be all you need. Compare prices instantly with Rx.com.